Aliases & Classifications for Urinary System Disease

MalaCards integrated aliases for Urinary System Disease:

Name: Urinary System Disease 12 15 17
Abnormality of the Urinary System 29 6
Congenital Malformation of the Urinary System 71
Non-Neoplastic Urinary System Disorder 71
Non-Neoplastic Urinary Tract Disease 12
Urinary Tract Diseases 54
Urinary Tract Disease 12
Urinary Tract Anomaly 54
Urologic Diseases 71

Classifications:



External Ids:

Disease Ontology 12 DOID:18
NCIt 49 C27599
UMLS 71 C0042075 C0158698 C1335051

Summaries for Urinary System Disease

Disease Ontology : 12 A disease of anatomical entity that is located in kidney, ureter, bladder and urethra.

MalaCards based summary : Urinary System Disease, also known as abnormality of the urinary system, is related to kidney disease and bladder disease, and has symptoms including dysuria, polyuria and urgency of micturition. An important gene associated with Urinary System Disease is B2M (Beta-2-Microglobulin), and among its related pathways/superpathways are MicroRNAs in cancer and SRF and miRs in Smooth Muscle Differentiation and Proliferation. The drugs leucovorin and Hydroxychloroquine have been mentioned in the context of this disorder. Affiliated tissues include kidney, prostate and smooth muscle.

Wikipedia : 74 The urinary system, also known as the renal system or urinary tract, consists of the kidneys, ureters,... more...

Related Diseases for Urinary System Disease

Diseases related to Urinary System Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 361)
# Related Disease Score Top Affiliating Genes
1 kidney disease 32.9 UMOD SIX1 NAGLU MIR199A1 MIR192 MIR17
2 bladder disease 32.9 MIR30A MIR29C MIR21 MIR199A1 MIR193A MIR17
3 urinary tract obstruction 31.5 UMOD NAGLU KLK3 CCR6 B2M
4 vesicoureteral reflux 1 31.2 UMOD SIX1 NAGLU B2M
5 uterine anomalies 31.1 MIR30A MIR29C MIR21 MIR199A1 MIR193A MIR17
6 myeloma, multiple 31.0 MIR30A MIR21 MIR199A1 MIR17 MIR126 ICOSLG
7 endometriosis 30.9 MIR29C MIR199A1 MIR145 MIR141 MIR126
8 cystic kidney disease 30.9 UMOD MIR30A MIR192 B2M
9 acute cystitis 30.8 UMOD KLK3 H2AC18 CCR6
10 bladder cancer 30.7 MIR29C MIR21 MIR193A MIR17 MIR145 MIR141
11 pyuria 30.4 KLK3 B2M
12 urethral stricture 30.2 MIR21 KLK3
13 exstrophy of bladder 11.5
14 congenital anomalies of kidney and urinary tract 1 11.4
15 alpha-thalassemia 11.2
16 chromosome 6q11-q14 deletion syndrome 11.2
17 hematuria, benign familial 11.0
18 cakut 11.0
19 urethral syndrome 11.0
20 bacteriuria 11.0
21 ureteral disease 11.0
22 lower urinary tract calculus 11.0
23 bone marrow cancer 10.9 MIR30A MIR21 MIR199A1 MIR17 MIR126 ICOSLG
24 mature b-cell neoplasm 10.9 MIR199A1 MIR17 ICOSLG H2AC18 CCR6 B2M
25 inherited metabolic disorder 10.9 NAGLU MIR21 MIR199A1 MIR17 MIR126 H2AC18
26 esophageal disease 10.9 MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR145
27 cervix disease 10.9 MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR145
28 leukocyte disease 10.9 MIR30A MIR21 MIR199A1 MIR17 MIR145 MIR126
29 overnutrition 10.9 MIR21 MIR199A1 MIR17 MIR126 ICOSLG H2AC18
30 bone inflammation disease 10.9 MIR30A MIR21 MIR199A1 MIR17 MIR126 ICOSLG
31 skin disease 10.9 MIR21 MIR199A1 MIR17 MIR126 ICOSLG H2AC18
32 mouth disease 10.9 MIR21 MIR199A1 MIR193A MIR17 MIR145 ICOSLG
33 autosomal genetic disease 10.9 MIR21 MIR199A1 MIR17 MIR126 ICOSLG H2AC18
34 immune system disease 10.9 MIR30A MIR21 MIR199A1 MIR192 MIR17 MIR126
35 bile duct disease 10.9 MIR30A MIR199A1 MIR17 MIR145 ICOSLG H2AC18
36 pancreas disease 10.9 MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR145
37 biliary tract disease 10.9 MIR30A MIR199A1 MIR17 MIR145 ICOSLG H2AC18
38 cell type benign neoplasm 10.9 MIR21 MIR199A1 MIR17 MIR126 H2AC18 CCR6
39 glucose metabolism disease 10.9 MIR30A MIR21 MIR199A1 MIR17 MIR141 MIR126
40 acquired metabolic disease 10.9 MIR30A MIR21 MIR199A1 MIR17 MIR141 MIR126
41 cardiovascular system disease 10.9 MIR21 MIR199A1 MIR17 MIR145 MIR126 ICOSLG
42 intrinsic cardiomyopathy 10.9 MIR30A MIR21 MIR199A1 MIR126 ICOSLG H2AC18
43 nervous system cancer 10.9 MIR30A MIR29C MIR21 MIR199A1 MIR193A MIR17
44 peripheral nervous system disease 10.9 MIR21 MIR126 ICOSLG H2AC18 CCR6 B2M
45 intestinal benign neoplasm 10.9 MIR21 MIR199A1 MIR192 MIR17 H2AC18 CCR6
46 central nervous system disease 10.9 MIR30A MIR21 MIR199A1 MIR17 MIR126 ICOSLG
47 thyroid gland disease 10.9 MIR30A MIR21 MIR199A1 MIR193A MIR17 ICOSLG
48 gastrointestinal system benign neoplasm 10.9 MIR21 MIR199A1 MIR192 MIR17 H2AC18 CCR6
49 lymphoma, non-hodgkin, familial 10.9 MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR126
50 disease of mental health 10.9 MIR30A MIR21 MIR199A1 MIR17 MIR126 H2AC18

Graphical network of the top 20 diseases related to Urinary System Disease:



Diseases related to Urinary System Disease

Symptoms & Phenotypes for Urinary System Disease

UMLS symptoms related to Urinary System Disease:


dysuria, polyuria, urgency of micturition, other and unspecified genitourinary symptoms, renal colic, pain in urethra, uti symptoms, urethral burning on micturition, loin pain, ureteral pain, flank tenderness, difficulty passing urine, urinary tenesmus, burning urination, bladder discomfort, renal pain, urologic problem

Drugs & Therapeutics for Urinary System Disease

Drugs for Urinary System Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 180)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
leucovorin Approved Phase 4 58-05-9 6006 143
2
Hydroxychloroquine Approved Phase 4 118-42-3 3652
3
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
4
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
5
Nitrofurantoin Approved, Vet_approved Phase 4 67-20-9 5353830
6
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
7
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
8
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
9
Uric acid Investigational Phase 4 69-93-2 1175
10 Antirheumatic Agents Phase 4
11 Micronutrients Phase 4
12 Trace Elements Phase 4
13 Vitamins Phase 4
14 Vitamin B Complex Phase 4
15 Vitamin B9 Phase 4
16 Nutrients Phase 4
17 Folate Phase 4
18 Antihypertensive Agents Phase 4
19 interferons Phase 4
20 Antiparasitic Agents Phase 4
21 Antiprotozoal Agents Phase 4
22 Angiotensin II Type 1 Receptor Blockers Phase 4
23 Giapreza Phase 4
24 Angiotensin Receptor Antagonists Phase 4
25 Immunoglobulin A Phase 4
26 Antimalarials Phase 4
27 Angiotensinogen Phase 4
28 Interferon-alpha Phase 4
29 Anti-Infective Agents Phase 4
30 Renal Agents Phase 4
31 Anti-Infective Agents, Urinary Phase 4
32 Anesthetics, Local Phase 4
33 Anesthetics Phase 4
34 Anticonvulsants Phase 4
35 Neuromuscular Agents Phase 4
36 Neuromuscular Blocking Agents Phase 4
37 Neuromuscular Nondepolarizing Agents Phase 4
38 Bromides Phase 4
39
Tamsulosin Approved, Investigational Phase 3 106133-20-4 129211
40
Mirabegron Approved Phase 3 223673-61-8 9865528
41
Propiverine Approved, Investigational Phase 3 60569-19-9 4942
42
tannic acid Approved Phase 3 1401-55-4
43
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
44
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
45
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
46
Lomefloxacin Approved, Investigational Phase 3 98079-51-7 3948
47
Ofloxacin Approved Phase 3 82419-36-1 4583
48
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
49
Somatostatin Approved, Investigational Phase 3 51110-01-1, 38916-34-6 53481605
50
Sodium citrate Approved, Investigational Phase 3 68-04-2

Interventional clinical trials:

(show top 50) (show all 122)
# Name Status NCT ID Phase Drugs
1 Periprocedural Administration of Folic Acid for Prevention of Contrast Induced Nephropathy in Patients Undergoing Coronary CTA/Angiography/Angioplasty Unknown status NCT02444013 Phase 4 Folic acid;Placebo
2 Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy:a Single Center Prospective Randomized Controlled Study Unknown status NCT02765594 Phase 4 Hydroxychloroquine Sulfate;Valsartan
3 A Long-Term, Open-Label, Prospective Phase IV Study to Assess the Safety and Efficacy of Nephoxil® in Subjects With End Stage Renal Disease (ESRD) on Dialysis Completed NCT03256838 Phase 4 Ferric Citrate
4 Nitrofurantoin Administration for the Prevention of Short-Term Catheter Associated Urinary Tract Infection After Pelvic Surgery (NAUTICA): A Randomized Controlled Trial Completed NCT03287089 Phase 4 Nitrofurantoin 100 MG;Placebo Oral Tablet
5 Efficacy of the Liposomal Bupivacaine for Postoperative Pain Control in Urologic Procedures Recruiting NCT02805504 Phase 4 Exparel;Marcaine
6 Does Depth of Neuromuscular Blockade (NMB) Affect Surgical Conditions and Postoperative Pain in Obese Patients Undergoing Robotic Surgery Recruiting NCT03591289 Phase 4 NMB with rocuronium bromide
7 Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Male Patients With Lower Urinary Tract Syndrome Completed NCT00239317 Phase 3 Tamusulosin
8 Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Female Patients With Lower Urinary Tract Syndrome Completed NCT00239265 Phase 3 Tamuslosin
9 A Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Subjects With Overactive Bladder (OAB) Treated With Antimuscarinics and Dissatisfied Due to Lack of Efficacy Completed NCT01638000 Phase 3 Mirabegron;Solifenacin succinate
10 An International Phase 3, Randomized, Double-Blind, Placebo- and Active (Tolterodine)-Controlled Multicenter Study to Evaluate the Safety and Efficacy of Vibegron in Patients With Symptoms of Overactive Bladder Completed NCT03492281 Phase 3 vibegron;Placebos;Tolterodine Tartrate ER
11 Efficacy and Tolerability of Propiverine Hydrochloride Extended Release (ER) Compared to Immediate Release (IR) in Patients With Neurogenic Detrusor Overactivity. A Randomized, Double Blind, Parallel Group, Multicenter Clinical Trial Completed NCT01530620 Phase 3 Propiverine hydrochloride ER (extended release);Propiverine hydrochloride IR (immediate release)
12 An International Phase 3, Randomized, Double-Blind, Active (Tolterodine)-Controlled Multicenter Extension Study to Evaluate the Long-Term Safety and Efficacy of Vibegron in Patients With Symptoms of Overactive Bladder Completed NCT03583372 Phase 3 Vibegron;placebos;Tolterodine Tartrate ER
13 A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder Completed NCT01972841 Phase 3 Solifenacin succinate;Mirabegron;Placebo to match solifenacin succinate;Placebo to match mirabegron
14 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Definitive Phase III Study of the Effects of Ferric Citrate on Serum Phosphate in Subjects With End Stage Renal Disease Completed NCT01503736 Phase 3 ferric citrate;ferric citrate;ferric citrate
15 A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate With Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects With Overactive Bladder Completed NCT02045862 Phase 3 Solifenacin succinate;Mirabegron;Placebo to match solifenacin;Placebo to match mirabegron
16 A Multicenter, Randomized Study To Compare The Safety And Efficacy Of Oral Levofloxacin With That Of Lomefloxacin HCl In The Treatment Of Complicated Urinary Tract Infections In Adults Completed NCT00258102 Phase 3 Levofloxacin
17 A Multicenter, Double-Blind, Randomized Study To Compare The Safety And Efficacy Of Oral Levofloxacin With That Of Ciprofloxacin HCl In The Treatment Of Complicated Urinary Tract Infections In Adults Completed NCT00258089 Phase 3 Levofloxacin
18 A Randomized, Double-Blind, Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects Who Have Received Solifenacin for 4 Weeks and Warrant Additional Relief for Their OAB Symptoms Completed NCT01908829 Phase 3 mirabegron 25 mg;mirabegron 50 mg;solifenacin 5 mg;solifenacin 10 mg;mirabegron 25 mg matching placebo;mirabegron 50 mg matching placebo;solifenacin 5 mg matching placebo;solifenacin 10 mg matching placebo
19 Effect of a Long-acting Somatostatin on Disease Progression in Nephropathy Due to Autosomal Dominant Polycystic Kidney Disease: a Long-term Three Year Follow up Study Completed NCT00309283 Phase 3 Long-acting somatostatin
20 CELLEBRATE: An Adaptive, Two-Stage, Double-Blind, Stratified, Randomized, Controlled Trial Comparing the Safety and Efficacy of AMDC-USR With Placebo in Female Subjects With Stress Urinary Incontinence Recruiting NCT03104517 Phase 3
21 A Multicenter, Randomized, Open‐Label, Active‐Controlled, Parallel Study to Assess the Efficacy and Safety of Ferric Citrate Capsules for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis Recruiting NCT03984760 Phase 3 Ferric Citrate;Sevelamer Carbonate
22 Perioperative Pregabalin as Part of a Multimodal Treatment Plan for Pain After Ureteroscopy With Stent Placement: a Pilot Active, not recruiting NCT03927781 Phase 3 Pregabalin 300mg
23 An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria Enrolling by invitation NCT04042402 Phase 3 DCR-PHXC
24 JPN1: A Confirmatory, Bridging, Double-Blind, Randomized, Controlled Trial in Japan Comparing the Safety and Efficacy of AMDC-USR With Placebo in Female Subjects With Stress Urinary Incontinence Not yet recruiting NCT03997318 Phase 3
25 A PHASE 3B, RANDOMIZED, OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MAINTENANCE THERAPY WITH VALRUBICIN VERSUS NO MAINTENANCE, IN SUBJECTS TREATED WITH VALRUBICIN INDUCTION FOR CARCINOMA IN SITU (CIS) OF THE BLADDER Terminated NCT01310803 Phase 3 VALSTAR - Maintenance Therapy
26 A Randomized Controlled Study Comparing Adjuvant Hyperthermia Treatment in Conjunction With Mitomycin C Versus BCG Immunotherapy (BCG) Adjuvant Treatment in Patients With Superficial Transitional Cell Carcinoma of the Bladder (STCCB) Terminated NCT00384891 Phase 3 Bacillus Calmette-Guérin
27 A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer Terminated NCT01200992 Phase 3
28 A Multi-Centre, Randomised, Open-Label Active-Controlled Study Comparing Safety and Efficacy of Synergo Radiofrequency (RF)-Induced Hyperthermia-Chemotherapy With Mitomycin C (RITE) Versus Bacillus Calmette-Guérin (BCG) as First-Line Treatment of Non-Muscle Invasive Papillary Bladder Cancer (NMIBC) Withdrawn NCT02254915 Phase 3 Bacillus Calmette-Guérin
29 A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effect of Adjuvant Treatment With Compound Cranberry Extract Tablets (UmayC) in Acute Bacterial Cystitis. Unknown status NCT00305071 Phase 2 compound cranberry extract tablet
30 A Randomized, Double-Blind, Factorial, Parallel-Group, Active and Placebo-Controlled, Multicenter Dose-Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Six Dose Combinations of Solifenacin Succinate and Mirabegron Compared to Mirabegron and Solifenacin Succinate Monotherapies in the Treatment of Overactive Bladder. Completed NCT01340027 Phase 2 Mirabegron;Solifenacin succinate;Placebo
31 A Multicenter, Single-Arm Study of the Effects of Atrasentan on Spermatogenesis and Testicular Function Completed NCT02118714 Phase 2 Atrasentan
32 RTA 402 Phase 2 Clinical Trial (A Randomized, Double-blind, Placebo-controlled Clinical Trial in Patients With Chronic Kidney Disease and Type 2 Diabetes) Completed NCT02316821 Phase 2 RTA 402;Placebo
33 Muscle Cell Mediated Therapy for Stress Urinary Incontinence in Males Following Prostate Surgery: An Investigation of Cook MyoSite Autologous Muscle Derived Cells Completed NCT02291432 Phase 1, Phase 2
34 A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Adaptive, Combined Proof of Concept and Dose-Finding Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the Treatment of Female Patients With Bladder Pain Syndrome / Interstitial Cystitis Completed NCT01613586 Phase 2 ASP3652;Placebo
35 Evaluation of the Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel Mixed With Mitomycin C (MMC) in Non-muscle Invasive Bladder Cancer (NMIBC) Patients Completed NCT02307487 Phase 2 120 mg MMC in 90ml gel;140 mg MMC in 90ml gel;160 mg MMC in 90ml gel;120 mg MMC in 60ml gel;140 mg MMC in 60ml gel;160 mg MMC in 60ml gel
36 A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients With Complicated Urinary Tract Infection (cUTI) Completed NCT01505634 Phase 2 Relebactam 250 mg;Relebactam 125 mg;imipenem/cilastatin 500 mg;Placebo to relebactam;Ciprofloxacin
37 A Phase 2 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria Recruiting NCT03847909 Phase 2 DCR-PHXC;Sterile Normal Saline (0.9% NaCl)
38 A Phase 1/2a Pilot Study of Intravesical TSD-001 for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer Recruiting NCT03081858 Phase 1, Phase 2 TSD-001
39 Efficacy of the Oncoxin-Viusid® Nutritional Supplement on the Quality of Life of Patients With Advanced or Metastatic Ovarian Epithelial Cancer. Clinical Trial Phase II. Recruiting NCT03562897 Phase 2
40 A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Administration of ALN-GO1 in Patients With Primary Hyperoxaluria Type 1 Enrolling by invitation NCT03350451 Phase 2 ALN-GO1
41 A Dose Escalation, Expansion Study of Vofatamab (B-701) Alone, Plus Docetaxel, or Versus Docetaxel in Subjects With Locally Advanced or Metastatic Urothelial Cell Carcinoma Who Have Relapsed After, or Are Refractory to Standard Therapy Terminated NCT02401542 Phase 1, Phase 2 Vofatamab;Docetaxel;Placebo
42 A Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy, Safety, and Tolerability of JNJ-42160443 in Subjects With Interstitial Cystitis/ Painful Bladder Syndrome Terminated NCT01060254 Phase 2 Placebo;JNJ-42160443
43 A Multi-Center, Open-Label Phase 1b/2 Study of a Novel FGFR3 Inhibitor (B-701) Combined With Pembrolizumab in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma Who Have Progressed Following Platinum-based Chemotherapy Terminated NCT03123055 Phase 1, Phase 2 B-701;Pembrolizumab
44 Clinical Study to Investigate the Safety and Pharmacokinetics of Udenafil Tablet in Renal Impaired Male Patients Completed NCT01232010 Phase 1 Mirodenafil
45 Clinical Study to Investigate the Safety and Pharmacokinetics of Udenafil Tablet in Renal Impaired Male Patients Completed NCT01231997 Phase 1 Udenafil
46 A Single-Dose, Randomised, Open-Label, Two-Period Crossover Study to Determine the Bioequivalence of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in the Fed State in Healthy Adult Male Subjects Completed NCT02058576 Phase 1 Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg;Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule
47 A Single-Dose, Randomised, Open-Label, Two-Period Crossover Study to Determine the Bioequivalence of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in the Fasted State in Healthy Adult Male Subjects Completed NCT02052713 Phase 1 Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg;Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule
48 A Phase I Investigation of the Safety, Tolerability and Immunogenicity of V934/V935 hTERT Vaccination in Cancer Patients With Selected Solid Tumors Completed NCT00753415 Phase 1
49 A Phase I Study for the Evaluation of Safety and Efficacy of Humacyte's Human Acellular Vascular Graft for Use as a Vascular Prosthesis for Hemodialysis Access in Patients With End-Stage Renal Disease Completed NCT01840956 Phase 1
50 Pilot Study of Mycophenolate Mofetil in Congenital Uropathies Completed NCT00193635 Phase 1 mycophenolate mofetil

Search NIH Clinical Center for Urinary System Disease

Genetic Tests for Urinary System Disease

Genetic tests related to Urinary System Disease:

# Genetic test Affiliating Genes
1 Abnormality of the Urinary System 29

Anatomical Context for Urinary System Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Urinary System Disease:

19
Kidney

MalaCards organs/tissues related to Urinary System Disease:

40
Kidney, Prostate, Smooth Muscle, Thyroid, Bone, Heart, Brain

Publications for Urinary System Disease

Articles related to Urinary System Disease:

(show all 44)
# Title Authors PMID Year
1
Forsythiaside A alleviates renal damage in adriamycin-induced nephropathy. 61
31585901 2020
2
Traditional Chinese medicine on treating chronic prostatitis/chronic pelvic pain syndrome: A systematic review and meta-analysis. 61
31261537 2019
3
Effectiveness comparisons of acupuncture for chronic prostatitis/chronic pelvic pain syndrome: A Bayesian network meta-analysis protocol. 61
31027066 2019
4
New method to preserve the original proportion and integrity of urinary cell-free DNA. 61
30175467 2019
5
Pilot study on serum C-reactive protein in pet rabbits: clinical usefulness. 61
31565226 2019
6
Risk factors and medical costs for healthcare-associated carbapenem-resistant Escherichia coli infection among hospitalized patients in a Chinese teaching hospital. 61
28095785 2017
7
Stem Cell Therapy for Treatment of Stress Urinary Incontinence: The Current Status and Challenges. 61
26880983 2016
8
Novel Transparent Urinary Tract Simulator Improves Teaching of Urological Operation Skills at a Single Institution. 61
25720440 2015
9
[Recent progress of small intestinal submucosa in application research of tissue repair and reconstruction]. 61
24279031 2013
10
[Retrograde nephrolithotripsy in patient with an abnormality of the urinary system]. 61
24159774 2013
11
Mortality causes in cancer patients with type 2 diabetes mellitus. 61
21960185 2012
12
Correlates of quality of life in China rural-urban female migrate workers. 61
21695594 2012
13
Synthesis and Vasorelaxant Effect of 9-aryl-1,8-acridinediones asPotassium Channel Openers in Isolated Rat Aorta. 61
24250444 2012
14
What do prostate cancer patients die of? 61
21257717 2011
15
[Epidemiological study of women adults with mixed urinary incontinence in China]. 61
20973221 2010
16
Epidemiology of mixed urinary incontinence in China. 61
20022321 2010
17
SIX1 acts synergistically with TBX18 in mediating ureteral smooth muscle formation. 54
20110314 2010
18
Thyroidization in renal allografts. 54
19594588 2009
19
Quantitative detection of cytokeratin 20 mRNA in urine samples as diagnostic tools for bladder cancer by real-time PCR. 54
19300416 2009
20
Prevalence of mutations in renal developmental genes in children with renal hypodysplasia: results of the ESCAPE study. 54
16971658 2006
21
[The results of surgery on HIV carriers with urinary system disease]. 61
16281512 2005
22
[Clinical evaluation of BTAstat, NMP22, HA, survivin, CD44v6, vEGF and VUC in bladder cancer diagnosis]. 54
16321281 2005
23
Practice of opportunistic prostate-specific antigen screening in Italy: data from the Health Search database. 54
15452450 2004
24
Health effects in community residents near a uranium plant at Fernald, Ohio, USA. 61
12921382 2003
25
[Implications of beta 2-microglobulin in the detection of associated urinary tract diseases in patients with infiltrative pulmonary tuberculosis]. 54
12577571 2002
26
[Significance of urinary nuclear matrix protein 22 in diagnosis of transitional cell carcinoma of urinary tract]. 61
12508552 2002
27
Inflamed urachal cyst containing calculi in an adult. 61
11981938 2002
28
Urine detection of survivin and diagnosis of bladder cancer. 54
11176843 2001
29
Urinary cytokeratin 20 as a marker for transitional cell carcinoma. 54
10765100 2000
30
Serum beta 2-microglobulin in fetuses with urinary tract anomalies. 54
9024089 1997
31
[Value of serum PSA and PAP measurement with newly developed latex turbidimetric immunoassay]. 54
7544063 1995
32
Urinary levels of the renal tubular enzyme N-acetyl-beta-D-glucosaminidase in unilateral obstructive uropathy. 54
8283554 1994
33
Use of serum gamma-enolase and aldolase A in combination as markers for renal cell carcinoma. 54
8486529 1993
34
Elevated levels of serum aldolase A in patients with renal cell carcinoma. 54
1509638 1992
35
Amniotic fluid N-acetyl-beta-D-glucosaminidase activity and renal abnormalities. 54
1750765 1991
36
[Prostatic specific antigen (PSA). Interpretation of results as a function of the assay method]. 54
1726942 1991
37
[Urinary Tamm-Horsfall protein coating of free cells and its clinical diagnostic significance]. 54
1864173 1991
38
[Prostate-specific antigen. Interpretation of the results in relation to the sampling method]. 54
1720942 1991
39
[Detection of beta-lactamase-producing strains isolated from urinary tract and their drug susceptibility]. 54
2399858 1990
40
Prostate-specific antigen in prostatic carcinoma. 54
1693455 1990
41
Comparison of urinary protein concentration and protein/creatinine ratio vs routine microscopy in urinalysis of dogs: 500 cases (1987-1988). 61
2793583 1989
42
Urinary tract endometriosis. 61
2921125 1989
43
Ultrasonography in the radiologic evaluation of children with urinary tract infection. 61
3523415 1986
44
The perplexing problem of prostatitis. 61
1181582 1975

Variations for Urinary System Disease

ClinVar genetic disease variations for Urinary System Disease:

6 ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 46;X;t(Y;3)(p11.2;p12.3)dnTranslocation Likely pathogenic 267818
2 CHD1L NM_004284.6(CHD1L):c.234C>T (p.Thr78=)SNV Uncertain significance 625178 rs1311096135 1:146724384-146724384 1:147252729-147252729

Expression for Urinary System Disease

Search GEO for disease gene expression data for Urinary System Disease.

Pathways for Urinary System Disease

Pathways related to Urinary System Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.77 MIR30A MIR29C MIR21 MIR199A1 MIR192 MIR17
2 10.07 MIR199A1 MIR145

GO Terms for Urinary System Disease

Cellular components related to Urinary System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.32 MIR30A MIR29C MIR21 MIR199A1 MIR192 MIR17

Biological processes related to Urinary System Disease according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of angiogenesis GO:0045766 9.67 MIR30A MIR21 MIR199A1 MIR126
2 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.61 MIR29C MIR21 MIR193A
3 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.5 MIR21 MIR199A1 MIR145
4 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.49 MIR199A1 MIR17
5 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.48 MIR199A1 MIR17
6 positive regulation of metalloendopeptidase activity GO:1904685 9.46 MIR21 MIR17
7 miRNA mediated inhibition of translation GO:0035278 9.46 MIR30A MIR21 MIR17 MIR145
8 negative regulation of vascular endothelial cell proliferation GO:1905563 9.43 MIR29C MIR193A MIR126
9 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.4 MIR21 MIR17
10 negative regulation of angiogenesis GO:0016525 9.35 MIR29C MIR21 MIR193A MIR145 KLK3
11 gene silencing by miRNA GO:0035195 9.32 MIR30A MIR29C MIR21 MIR199A1 MIR193A MIR192

Molecular functions related to Urinary System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.32 MIR30A MIR29C MIR21 MIR199A1 MIR193A MIR192

Sources for Urinary System Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....